trending Market Intelligence /marketintelligence/en/news-insights/trending/_pXQlfJnhEkKmcdVwU1osg2 content esgSubNav
In This List

US FDA approves Alembic Pharmaceuticals' fungal infection capsules

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


US FDA approves Alembic Pharmaceuticals' fungal infection capsules

Alembic Pharmaceuticals Ltd. said the U.S. FDA approved its abbreviated new drug application for 100-milligram itraconazole capsules for the treatment of fungal infections including blastomycosis, histoplasmosis and aspergillosis.

The approved drug is therapeutically equivalent to Janssen Pharmaceuticals' Sporanox capsules.